| Scorecard |
|---|
|
2 / 5 Stars
|
|
Lipper
2
1
4
3
3
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
1 / 5 Stars
|
|
TheStreet.com
C+
(Hold)
|
#31 in Health
U.S. News evaluated 38 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 15.67 percent over the past year, 10.08 percent over the past three years, 8.93 percent over the past five years, and 9.90 percent over the past decade.
| Trailing Returns | Updated 04.30.2013 |
|---|---|
| Year to date | 8.2% |
| 1 Year | 15.7% |
| 3 Years (Annualized) | 10.1% |
| 5 Years (Annualized) | 8.9% |
| 10 Years (Annualized) | 9.9% |
Summary
The investment seeks to provide long-term growth by investing principally in the common stocks of companies in the life sciences industry. The fund will invest, under normal circumstances, at least 80% of its net assets in securities of companies involved in the life sciences industry. Examples of the companies in which the Series may invest include those in the following areas: pharmaceuticals, biotechnology, medical products and supplies, health care services, and environmental services. The fund may invest in U.S. and foreign stocks, including those in emerging markets, ADRs and other U.S. dollar denominated securities of foreign issuers.
Fees
Fees are Low compared to funds in the same category.
Manning & Napier Life Sciences Series Fund has an expense ratio of 1.16 percent.
Risk
Risk is Above Average compared to funds in the same category according to Morningstar.
